Drug Names Jan 19, 2023 Gene Signature Beats TILs as Biomarker of Response to Anti-HER2 Therapy Premium Jan 19, 2023 Liquid Biopsy Biomarker Score Predicts Relapse in Lymphoma Patients After CAR T-Cell Treatment Premium Jan 18, 2023 Penn Scientists Testing Out CAR T-Cell Therapy Gel to Prevent Breast Cancer Recurrence Post-Surgery Premium Jan 6, 2023 BioNTech, UK Government to Expand Access to Personalized mRNA Cancer Vaccines in England Jan 4, 2023 Precision Oncology in 2022: New Drugs and Tests Amid Ongoing Access Barriers Premium Dec 30, 2022 Top 10 Precision Oncology Stories in 2022: Liquid Biopsy, Radioligands, HER2-Low, Data Sharing Dec 22, 2022 Gilead Sciences, Arcus Biosciences Tout Domvanalimab NSCLC Data as Good News for Anti-TIGIT Approach Premium Dec 20, 2022 NICE Backs Enhertu via Managed Access Program for Certain HER2-Positive Breast Cancer Patients Dec 20, 2022 Moderna's Oncology Aspirations Grow With mRNA Vaccine Success in Melanoma Premium Dec 13, 2022 Amgen to Seek Blincyto Approval in MRD-Negative ALL Following Positive Phase III Results Premium Dec 13, 2022 Gilead's Yescarta Safe and Effective for CNS Lymphoma Patients, Pilot Study Shows Premium Dec 8, 2022 Daiichi Sankyo Transfers Rights to Market Yescarta in Japan to Gilead Sciences Dec 7, 2022 SABCS Data Solidifies Enhertu as Preferred Second-, Third-Line HER2-Positive Breast Cancer Treatment Premium Dec 7, 2022 Enhertu Shows Activity in Early-Stage HER2-Low Breast Cancer Patients in Study Reported at SABCS Dec 1, 2022 Nectin Therapeutics Enters Clinical Stage With Drug for Non-Responders to Checkpoint Inhibitors Premium Nov 30, 2022 Addario Lung Cancer Medical Institute Begins Study Exploring KRAS Inhibitor Resistance Nov 30, 2022 Erasca Inks Deal With Pierre Fabre on ERAS-007, Braftovi Combo Study in Colorectal Cancer Nov 29, 2022 Genentech to Withdraw First-Line Tecentriq Bladder Cancer Indication Nov 28, 2022 NICE Recommends BMS's Opdivo Plus Chemo for HER2-Negative, PD-L1-Positive Gastric Cancer Nov 23, 2022 Higher TIL Levels in Residual Disease May Predict Worse Survival in HER2-Positive Breast Cancer Premium Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
